<DOC>
	<DOCNO>NCT01245361</DOCNO>
	<brief_summary>Patient undifferentiated arthritis presence anti-citruline ( anti-CCP ) antibody high risk develop RA . The presence anti-CCP associate high rate erosion high risk progressive severe RA . The investigator demonstrate CIERA study MTX/IFX combination therapy superior MTX alone reduce MRI sign synovitis bone edema clinically effective . The immunopathogenesis undifferentiated arthritis poorly understood . However , synovial study patient early arthritis suggest UA RA may share common immunopathogenic mechanism . One biopsy study asymptomatic joint patient early arthritis demonstrate synovitis half joint sample prominent T cell macrophage infiltration , similar Rheumatoid Arthritis ( RA ) . Thus intensive treatment anti-TNF antibody ( infliximab ) may impact multiple immune mechanism drive synovitis undifferentiated arthritis may influence clinical outcome . Recently , Methotrexate demonstrate improve course undifferentiated arthritis prevent development RA . Short regimen intensive therapy Infliximab could alter radiological , immunopathological clinical outcome .</brief_summary>
	<brief_title>A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA : Clinical , Radiological And Synovial Benefit</brief_title>
	<detailed_description>necessary</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Diagnosis UA Absence American College Rheumatology ( ACR ) criterion Active UA define swollen joint count â‰¥ 1 &lt; 4 Positive antiCCP Disease duration &lt; 2 year DMARDs naive No chronic treatment steroid ( &gt; 3 month ) , need washout 4 week NSAIDs stable Other rheumatic inflammatory diagnosis Contraindication MRI ( pacemaker , etc . ) Congestive heart disease Active latent tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Undifferentiated Arthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Infliximab</keyword>
</DOC>